- Home
- BCAB vs TCRT Comparison
BCAB vs TCRT Comparison
Compare BCAB & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCAB | TCRT |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 4.9M |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | BCAB | TCRT |
|---|---|---|
| Price | $3.04 | $1.86 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 47.9K | 8.6K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.86 | 24.66 |
| EPS | N/A | ★ N/A |
| Revenue | $300,000.00 | ★ $15,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $1.67 |
| 52 Week High | $6.52 | $4.57 |
Technical Indicators
Market Signals| Indicator | BCAB | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 36.30 | 40.13 |
| Support Level | $0.17 | $1.81 |
| Resistance Level | $4.24 | $2.02 |
| Average True Range (ATR) | 0.28 | 0.08 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 22.26 | 36.36 |
Price Performance
Historical ComparisonAbout BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.